Condition: Upper Limb Spasticity (ULS) · Sponsor: JHM BioPharma (Tonghua) Co. , Ltd.
This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A(Eveotox)in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.
This description comes directly from the study's public registry record.
Danhua Lin · 15811460241 · danhua.lin@jhm-biopharma.com
Lei Wang · lei.wang@jhm-biopharma.com
Always discuss trial participation with your own doctor first.
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The Second Hospital of Hebei Medical Hospital | Shijiazhuang, Hebei, China | Recruiting |
| Luoyang Central Hospital | Luoyang, Henan, China | Recruiting |
| The Second Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Huai 'an Second People's Hospital | Huai'an, Jiangsu, China | Active Not Recruiting |
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Pingxiang People's Hospital | Pingxiang, Jiangxi, China | Recruiting |
| Shengjing Hospital affiliated to China Medical University | Shenyang, Liaoning, China | Recruiting |
| Yantai Mountain Hospital | Yantai, Shandong, China | Recruiting |
| Huashan Hospital Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Yangzhi Affiliated Rehabilitation Hospital of Tongji University | Shanghai, Shanghai Municipality, China | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.